Related references
Note: Only part of the references are listed.Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years
Sungju Kim et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
The Expiry of Humira(R) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Evelien Moorkens et al.
FRONTIERS IN PHARMACOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Brian Godman et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018
Patrick C. DeMartino et al.
JAMA INTERNAL MEDICINE (2021)
Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
Jong Hyuk Lee
HEALTHCARE (2021)
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
Caridad Pontes et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2020)
Defining the concept of fair pricing for medicines
Suerie Moon et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System
Ji Ryoun Gong et al.
CLINICAL THERAPEUTICS (2020)
Managed Entry Agreements: Policy Analysis From the European Perspective
Monique Dabbous et al.
VALUE IN HEALTH (2020)
Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland
Kelly Baillie et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
Consolacion Molto et al.
CANCER (2020)
Integrative Review of Managed Entry Agreements: Chances and Limitations
Carolina Zampirolli Dias et al.
PHARMACOECONOMICS (2020)
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
Rick Vreman et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Jane F. Barlow et al.
VALUE IN HEALTH (2019)
The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost
Vaishali Shukla et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2019)
International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review
P. Lasalvia et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2019)
Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation
Myrto Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System
Seung-Lai Yoo et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment
Jason C. Hsu et al.
PLOS ONE (2019)
Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
P. Frisk et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Outrageous prices of orphan drugs: a call for collaboration
Lucio Luzzatto et al.
LANCET (2018)
Sustainability and affordability of cancer drugs: a novel pricing model
Carin A. Uyl-de Groot et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
Jacoline C. Bouvy et al.
FRONTIERS IN PHARMACOLOGY (2018)
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
Brian Godman et al.
FRONTIERS IN PUBLIC HEALTH (2018)
Performance-Based Risk-Sharing Arrangements: An Updated International Review
Josh J. Carlson et al.
PHARMACOECONOMICS (2017)
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
Alessandra Ferrario et al.
PHARMACOECONOMICS (2017)
A Multiple Streams analysis of the decisions to fund gender-neutral HPV vaccination in Canada
Gilla K. Shapiro et al.
PREVENTIVE MEDICINE (2017)
Cancer drugs: high price, uncertain value
Deborah Cohen
BMJ-BRITISH MEDICAL JOURNAL (2017)
National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea
Eun-Sook Kim et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2017)
Cancer drugs: high price, uncertain value
Deborah Cohen
BMJ-BRITISH MEDICAL JOURNAL (2017)
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
Kim Pauwels et al.
FRONTIERS IN PHARMACOLOGY (2017)
Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders
Tara Nazareth et al.
Journal of Managed Care & Specialty Pharmacy (2017)
Drug Pricing in South Korea
Hye-Young Kwon et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)
Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements
Panos Kanavos et al.
GLOBAL POLICY (2017)
Utilisation of the ESMO-MCBS in practice of HTA
C. Wild et al.
ANNALS OF ONCOLOGY (2016)
Eight-year experience of using HTA in drug reimbursement: South Korea
Eun-Young Bae et al.
HEALTH POLICY (2016)
Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
Alessandra Ferrario et al.
SOCIAL SCIENCE & MEDICINE (2015)
Towards universal coverage: an evaluation of the benefit enhancement plan for four major conditions in Korean National Health Insurance
Yoon Kim
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION (2014)
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Thomas Morel et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
What principles should govern the use of managed entry agreements?
Marianne Klemp et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
Jakub Adamski et al.
BMC HEALTH SERVICES RESEARCH (2010)
Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
Josh J. Carlson et al.
HEALTH POLICY (2010)
Share Paper
